Home > Support & Survivorship > Spring, 2008, Thrive

New Therapies, New Hope

The Ravitz Foundation Phase 1/Translational Research Center recently opened its doors to its fi rst clinical trial volunteers. With that important step, the U-M Cancer Center kicked off its newest effort to speed promising therapies from the laboratory to the clinic -- where you, our patient, may ultimately benefit.

Led by Moshe Talpaz, M.D. -- an internationally renowned researcher who helped to develop Gleevec, one of the most effective targeted treatments developed for cancer -- the center is examining potential drugs and therapies for all types of cancer at the earliest stage of the FDA approval process. Phase 1 trials usually involve a small number of people who have not benefited from currently available treatments.

 

Related Resources

To learn more about what clinical trials are, please visit our Clinical Trials web pages.

To find out which clinical trials are now accepting volunteers, visit Engage, the University of Michigan's clinical trials resource, or call the Cancer AnswerLine at 1-800-865-1125.

Tell us what you think.

What kinds of stories would you like to reading in Thrive? What type of advice do you think would be helpful? Do you have tips for other patients or caregivers? Let us know. Email us at ThriveMagazine@med.umich.edu.

return to the top of the page

Check It Out
Find out what's going on in the Patient & Family Center this month.

Adjust text size

University of Michigan Comprehensive Cancer Center
1500 East Medical Center Drive
Ann Arbor, MI 48109

This site is part of the U-M Health System. The information presented is not a tool for self diagnosis or a substitute for professional care. © 2008 U-M Comprehensive Cancer Center